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Abstract
Background Physician patterns of screening for hepatitis B
(HBV) and hepatocellular carcinoma (HCC) among Asian
Americans are not well described.
Aims To describe HBV and HCC screening practices
among providers with large Asian American populations.
Methods Providers within San Francisco’s safety net
system were surveyed with respect to HBV and HCC
screening practices as well as knowledge, attitudes, and
barriers to HCC screening.
Results Among the 109 respondents (response rate =
72%), 62% were aged [40, 65% female, 24% Asian, 87%
primary care providers, and 48% had[25% Asian patients.
Only 76% had screened [50% of their Asian patients for
HBV and 43% had vaccinated [50% of eligible patients
against HBV. Although 94% knew Asians were dispropor-
tionately affected by HCC, only 79% had screened for HCC
in [50% of their Asian patients with chronic hepatitis B
(CHB). A majority believed that HCC screening in CHB
reduces HCC mortality (70%) and is cost-effective (57%).
The most common HCC screening modality was AFP with
abdominal ultrasound every 6–12 months (63%). Factors
associated with HBV screening were familiarity with
AASLD guidelines (OR 6.4, 95% CI 1.3–30.1, p = 0.02)
and having vaccinated [50% of eligible patients against
HBV (OR 2.2, 95% CI 1.1–4.5, p = 0.03). Factors associ-
ated with HCC screening using abdominal ultrasound every
6–12 months were having[25% Asian patients (OR = 4.5,
95% CI 1.3–15.3, p = 0.02) and higher HCC knowledge
score (OR = 1.9 per item, 95% CI 1.01–3.6, p = 0.045).
Conclusions HBV and HCC screening rates and HBV
vaccination among Asians from physician report is sub-
optimal. HCC screening is associated with having more
Asian patients and higher provider knowledge. Provider
education is essential in increasing rates of HBV and HCC
screening among Asian Americans.
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Introduction
Approximately 1.25 million Americans have chronic hep-
atitis B infection (CHB). Patients with CHB are at signif-
icant lifetime risk for developing cirrhosis, liver failure,
and hepatocellular carcinoma (HCC) [1]. CHB is especially
prevalent among Asians and these patients have a threefold
or greater increase in the rate of HCC as compared to non-
Hispanic Whites [2–4]. The prevalence of CHB varies
nationwide due largely to immigration patterns from high-
risk areas. In the San Francisco Bay Area, where one-
fourth of the population is from the highly endemic regions
of Asia and the Pacific Islands, the reported prevalence of
CHB is as high as 9% among these individuals [5].
Moreover, in 2006 the San Francisco Department of Public
Health reported that 84% of probable cases of HBV
infection occurred in the Asian American and Pacific
Islander (AAPI) populations [6]. Thirty percent of the
patients in the San Francisco’s safety net healthcare system
are AAPIs [7]. Most of the patients in this system are
uninsured or underinsured and have significant health care
disparities [8, 9]. In order to reduce the burden of HCC
among AAPIs, it is important that these patients are
screened for HBV and, depending on their status, receive
HBV vaccination or HCC screening as appropriate, espe-
cially within the safety net healthcare systems [10].
Hepatocellular carcinoma screening can detect early
stage disease and may improve survival in the presence of
curative treatment options [11]. Practice guidelines pub-
lished by the American Association for the Study of Liver
Diseases (AASLD) recommend HCC screening in high-risk
populations, including Asians with CHB [12]. The recom-
mended screening test is liver ultrasound every 6–12 months.
Studies have shown that the majority of providers recom-
mend HCC screening to their patients [13, 14], however,
there is no information on the screening modalities typically
employed by providers within the context of CHB infection.
In addition, although there is limited data on provider
knowledge, attitudes, and perceived barriers to HCC sur-
veillance among HBV-infected Asian Americans [14, 15],
there are no studies evaluating these factors within the
resource-limited safety net healthcare systems. This infor-
mation is crucial in identifying interventions to reduce dis-
parities in health and health care in this at-risk population.
In this study we aimed to characterize provider-reported
screening practices for HBV and HCC along with provider
knowledge, attitudes, and perceived barriers to HCC
screening among Asian Americans by surveying a large
network of providers within San Francisco’s safety net
healthcare system.
Methods
Study Design
This was a cross-sectional survey of primary care and
specialty providers who provide health care in clinics
affiliated with the San Francisco’s safety net healthcare
system, which annually provides care for over 150,000
patients, including most of the county’s uninsured residents
[7]. This system is composed of the San Francisco Com-
munity Clinic Consortium, which has ten nonprofit primary
care community health centers, and the San Francisco
Department of Public Health’s Community Health Net-
work, which includes 11 community-based primary care
clinics and one acute care hospital (San Francisco General
Hospital) with on-site primary and specialty care clinics
[7]. The survey was sent to the 150 providers from these
primary care clinics and three specialty (gastroenterology,
hepatology, HIV/infectious diseases) clinics by mail or
electronic mail between December 1, 2007, and March 31,
2008. A second mailing to non-respondents was conducted
after 4 weeks. Respondents chose a $10 gift certificate or a
chance for a $100 gift card as incentives. The study was
approved by the Committee on Human Research of the
University of California, San Francisco, and the SFGH
Data Governance Committee.
Survey Design
The survey instrument was developed by the study inves-
tigators with input from hepatology expert opinion and
previously published surveys. Content domains included
provider and practice characteristics, HBV screening and
CHB management practices, HCC surveillance practices
and modalities employed, provider knowledge of HBV and
HCC, and attitudes toward (and perceived barriers to) HCC
surveillance. The survey was pilot-tested with 20 physi-
cians and revised.
Data Definitions and Statistics
Provider and practice characteristics were summarized
using mean ± SD, median (range), and frequencies. In
order to assess overall provider knowledge, favorable
attitudes, and barriers to performing HCC surveillance,
scores were formed from the responses to questions
assessing these factors. The knowledge score was
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computed as the number of correct responses to the four
questions assessing knowledge (minimum 0, maximum 4).
The attitude score was determined by summing the
numerical codes assigned to responses to eight questions
assessing provider attitudes as follows: 1 to an ‘‘agree’’
response, 0.5 to ‘‘unsure’’ response, and ‘‘0’’ to a ‘‘dis-
agree’’ response. The barrier score was computed as the
number of barriers from a list of 11 categories including
an ‘‘other’’ category identified by the providers. Screening
for HCC was defined as performing ultrasound every
6–12 months. To evaluate provider and practice factors
associated with HBV and HCC screening, univariate
analysis was performed using Student’s t test for continu-
ous variables and Chi-square (Fishers exact test when
appropriate) tests for categorical variables. Multivariable
logistic regression modeling evaluating factors associated
with HBV and HCC screening included independent pre-
dictors from an a priori compiled list as well as those with a
p value B0.2 as determined by the univariate analysis.
Statistical significance was assessed at the p value of\0.05
level (two-sided) in all models. All analyses were per-
formed using STATA version 8.0 (STATA Corporation,
College Station, TX).
Results
Provider and Practice Characteristics
Out of 150 providers, 109 returned the survey, a response
rate of 72%. Provider characteristics are shown in Table 1.
Most (87%) were primary care providers, 9% were hepa-
tologists and gastroenterologists, and 80% held an MD
degree. The majority were above age 40 and 65% were
female. Thirty-one percent were Asian and half had been in
practice for more than 10 years. Twenty-four percent of all
providers and 77% of the Asian providers spoke an Asian
language. About half (48%) reported that Asian patients
comprised over 25% of their patient population and 53%
reported that among their Asian patients, more than 50%
had limited English proficiency. The majority of patients in
the practices surveyed were either uninsured or had public
insurance.
HBV Screening, Vaccination, and HCC Screening
Provider management practices relating to HBV screening,
HBV vaccination, and HCC surveillance among Asian
patients are summarized in Table 2. Only 76% of the
providers reported that [50% of their Asians patients had
been screened for HBV. Only 43% of the providers
reported that [50% of their eligible patients had received
HBV vaccination. A multitude of HBV screening practices
were reported: 48% ordered HBsAg only; 16% used
HBsAg and anti-HBs in combination; 24% used HBsAg in
combination with anti-HBs and total anti-HBc; 9% used
HBsAg and total anti-HBc; 2% used anti-HBc; and 1%
used HBV viral load.
There was also considerable variation in defining high-
risk populations for HCC screening—60% would screen all
patients with CHB, 11% would screen Asian patients with
CHB, 6% would screen only in patients with HBV-induced
cirrhosis, and 23% would screen a combination of these
Table 1 Provider and practice characteristics in the San Francisco
safety net healthcare system
Age (%) (years)
20–29 6
30–39 29
40–49 28
50–59 28
C60 9
Female (%) 65
Race/ethnicity (%)
Caucasian 61
African-American 1
Asian/Pacific Islander 31
Latino 6
Other 1
Born in United States (%) 85
Speak Asian language (%) 24
Post-graduate degree (%)
MD 80
Nurse practitioner 17
Other 3
Specialty (%)
Internal medicine 46
Family practice 41
Gastroenterology/hepatology 9
Infectious disease 2
Other 2
Years in practice (%)
0–10 50
11–20 43
[20 7
Median number of patients seen per week (range) 30 (5–100)
More than 25% Asian patients 48
More than 50% of Asian patients with limited English
proficiency
53
Median proportion of patients in practice with
Private insurance 5
Public insurance 50
Uninsured 40
(n = 109)
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groups. Only 79% reported that they had screened for HCC
in[50% of their Asian patients with CHB. Although 27%
of providers were unfamiliar with the AASLD guidelines
for HCC screening in HBV patients, 94% reported that they
perform HCC screening among CHB patients.
HCC Screening Modalities
Providers were asked to report which of several laboratory
or imaging studies they used for HCC screening, either
alone or in combination. Overall, 91% used alpha feto-
protein (AFP); 79% used ultrasound (US); 71% used AST
and/or ALT; 46% used other imaging modalities; and 30%
used HBV viral load (Fig. 1). The most commonly used
modalities reported were AFP (90%) and US (78%) at a
frequency of every 6–12 month. Among the 88% who
indicated that they used a combination of AFP and an
imaging study for HCC surveillance every 6–12 months,
63% used US, 8% used computed tomography (CT), and
29% used more than one type of imaging. Only 3% of
respondents used AFP alone and 5% used imaging alone
for HCC surveillance.
Provider Knowledge, Attitudes, and Barriers to HCC
Screening
Knowledge, attitudes, and barriers to HCC screening are
summarized in Table 3. Nearly all providers knew that
CHB was the most common cause of HCC among Asians
and that Asians had a higher incidence of HCC compared
to Whites. Three-quarters indicated that treating CHB can
prevent HCC. About 70% believed that HCC screening in
patients with CHB reduces HCC mortality and over half
thought that screening is cost-effective and not screening
poses a malpractice risk. The most common factors that
influence a provider’s decision to order any cancer-
screening test were recommendations by a national orga-
nization (93%) and good evidence that screening decreases
mortality (99%). The most common perceived barriers
influencing a provider’s decision to perform HCC screen-
ing among patients with CHB were lack of imaging
resources (59%), unclear HCC screening guidelines (35%),
difficulty accessing specialty care (35%), and patient
financial barriers (31%).
Table 2 HBV screening, vaccination, and management among San
Francisco safety net providers
Screening and management Proportion (%)
Proportion of Asian patients that have been screened for HBV
B25% 10
26–50% 11
51–74% 26
C75% 50
Not sure 3
Proportion of eligible patients that have been vaccinated against HBV
B25% 25
26–50% 21
51–74% 26
C75% 17
Not sure 11
Proportion of Asian patients with chronic HBV that have been
vaccinated against HAV
B25% 17
26–50% 10
51–74% 11
C75% 50
Not sure 12
Proportion of Asian patients with chronic HBV that have been
screened for HCC
B25% 4
26–50% 10
51–74% 13
C75% 66
Not sure 7
Offers therapy for HBV 35
HAV hepatitis A virus, HBV hepatitis B virus, HCC hepatocellular
carcinoma
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Fig. 1 Hepatocellular carcinoma screening modalities utilized by
providers. The providers were asked whether they used any of the
following laboratory and abdominal imaging modalities as a screen-
ing tool for hepatocellular carcinoma. The figure summarizes the
responses of providers with regards to the type of test and the
frequency of the test used in their practice for hepatocellular
carcinoma surveillance. AFP alpha fetoprotein, AST aspartate
aminotransferase, ALT alanine aminotransferase, US ultrasound, CT
computed tomography, MRI magnetic resonance imaging, HBV DNA
hepatitis B viral load
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Factors Associated with Performing the Recommended
HBV and HCC Screening
Factors associated with the higher likelihood of reporting
HBV screening among [50% of Asian patients in univar-
iate analysis included having performed HBV vaccination
in [50% of eligible patients (94 vs. 60%, p \ 0.0001),
HCC screening in [50% of CHB patients in practice (86
vs. 43%, p \ 0.0001), familiarity with AASLD guidelines
(84 vs. 52%, p = 0.001), and provider age less than
40 years (88 vs. 68%, p = 0.02). The rate of HBV
screening (in more than 50% of their Asian patients) was
not significantly different among those providers who
spoke an Asian language versus those who did not speak an
Table 3 Provider knowledge, attitudes, and barriers towards hepatocellular carcinoma (HCC) surveillance
Knowledge (mean score 3.3 ± 0.8) Correct answers (%)
Asians have same incidence of liver cancer as Whites 94
Most common cause of liver cancer in Asians is HBV 95
Treating HBV can prevent liver cancer 77
HCC screening in HBV reduces liver cancer mortality 70
Attitude (mean score = 5.8 ± 1.6) Percent agree
Not screening for HCC is a malpractice risk 59
Screening for HCC is cost-effective 57
Will perform cancer screening when it is recommended by a national organization 93
Will perform cancer screening when my patients ask for it 69
Will perform cancer screening when it is used as a quality measure at my institution or by insurance companies 72
Will perform cancer screening when it is covered by health insurance 62
Will perform cancer screening when I see an increasing frequency of cancer in my practice 56
Will perform cancer screening when there is good evidence that screening leads to decreased mortality 99
Provider perceived barriers (mean score = 2.3 ± 1.7) Percent agree
Lack of clarity of liver cancer-screening guidelines 35
Discomfort with discussing liver cancer screening 1
Lack of effectiveness of cancer screening 12
Lack of US/CT/MRI screening resources 59
Lack of effective therapy for liver cancer 15
Difficulty accessing specialty (GI/hepatology) care 35
Lack of blood testing resources 4
Language access barriers with patient 18
Patient financial barriers 31
Uncertain/unaware of liver cancer screening guidelines 27
HBV hepatitis B virus, HCC hepatocellular carcinoma
Table 4 Multivariate
regression analysis of factors
associated with hepatocellular
carcinoma screening with
abdominal ultrasound every
6–12 months
Variable Odds ratio 95% CI p value
Age (per decade) 0.7 0.3–1.7 0.5
Female gender 0.5 0.1–1.6 0.2
Provider race (Asian vs. non-Asian) 0.4 0.1–1.6 0.2
More than 10 years in practice 1.3 0.3–6.7 0.3
Specialty (primary care vs. GI/hepatology) 0.2 0.03–1.1 0.06
Familiarity with AASLD practice guidelines on HCC screening 1.9 0.5–6.5 1.0
More than 25% Asian patients in practice 4.5 1.3–15.3 0.02
Provider knowledge score 1.9 1.01–3.6 0.045
Provider attitude score 1.1 0.8–1.6 0.5
Provider barrier score 1.01 0.7–1.4 0.06
1520 Dig Dis Sci (2011) 56:1516–1523
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Asian language (88 vs. 70%, p = 0.07). In addition,
although a higher rate of HBV screening was reported by
providers at safety net health centers with a high proportion
of Asian providers who speak an Asian language, this did
not reach statistical significance (90 vs. 72%, p = 0.07).
On multivariable analysis when controlling for provider
age, gender, race, years in practice, and specialty, famil-
iarity with AASLD guidelines (OR 6.4, 95% CI 1.3–30.1,
p = 0.02) and having vaccinated against HBV in[50% of
eligible patients (OR 2.2, 95% CI 1.1–4.5, p = 0.03) were
significantly associated with a higher likelihood of report-
ing HBV screening among [50% of Asian patients.
For HCC screening, in univariate analysis, performing
US every 6–12 months was associated with having [25%
or more Asian patients [53% (45/85) vs. 25% (6/24),
p = 0.02] and higher knowledge score (3.0 ± 0.9 vs.
3.4 ± 0.8, p = 0.01). There was no statistically significant
difference in performing US every 6–12 months among
providers who spoke an Asian language compared to those
who did not speak an Asian language (88 vs. 75%,
p = 0.2) and among providers from centers with a high
proportion of Asian providers who spoke an Asian lan-
guage compared to those who did not practice at these
centers (90 vs. 75%, p = 0.1). In multivariate analysis after
controlling for provider age, gender, race, years in practice,
and medical specialty the same two variables, having
[25% of Asian patients in the practice (OR = 4.5, 95% CI
1.3–15.3, p = 0.02) and having a higher knowledge score
(OR = 1.9, 95% CI 1.01–3.6, p = 0.045), remained sig-
nificantly associated with performing ultrasound every
6–12 months (Table 4).
Discussion
This is the first study to evaluate provider-reported HBV
and HCC screening practices as well as knowledge, atti-
tudes, and barriers towards HCC screening among Asian
Americans in a safety net healthcare system. Respondents
reported suboptimal rates of screening for and vaccination
against HBV among Asians and screening for HCC. Hav-
ing a higher rate of HBV vaccination in practice and
familiarity with AASLD guidelines was associated with
higher rates of HBV screening whereas having a large
proportion of at-risk Asian patients and greater provider
knowledge of HCC’s relationship to HBV were associated
with HCC screening.
At the time of this survey, the Center for Disease
Control and Prevention (CDC) recommended HBV
screening in Asian and Pacific Islanders and vaccination of
all eligible at-risk patients. The current HBV screening
recommendations also include US born persons not vac-
cinated as infants whose parents were born in regions with
high HBV endemicity [16]. The recent Institute of Medi-
cine Hepatitis and Liver Cancer Report also emphasizes the
importance of HBV screening and vaccination [17]. Stud-
ies to date have shown that HBV screening and vaccination
among Asian Americans are suboptimal at rates of 35–65%
[15, 18–20]. Similarly, only half of the providers in this
study estimated that 75% or more of their Asian patients
were screened for HBV infection and less than half of the
providers had vaccinated the majority of their eligible
Asian patients. Both patient and provider factors impact
HBV screening and vaccination and provider knowledge
represents an especially important factor [14, 17]. Previous
studies have shown that Asians are more likely to get
screened and vaccinated against HBV if recommended
by a medical provider [18]. In contrast, the lack of patient
English-language fluency and low socioeconomic status are
associated with lower rates of HBV screening and vacci-
nation [21]. The majority of the patients in the practices
surveyed in this study had low socioeconomic status and
were uninsured or had public medical insurance and
approximately half of the providers indicated that more
than 50% of their Asian patients spoke little or no English.
Our results, however, did not show an association between
provider race (Asian vs non-Asian) or ability to speak an
Asian Language and increased HBV or HCC screening.
This finding may be due to the sample size, which may not
be adequately powered to detect a difference. However,
while one might expect that providers who are Asian or
who speak an Asian language may have a heightened
awareness of hepatitis B and better communicate the need
for HBV and HCC screening to their patients, the data in
the literature are conflicting. While there are reports of
providers with Asian language abilities performing more
HBV screening among Chinese-speaking patients [15],
others have not found an association between provider
race (Asian vs non-Asian) and Asian language and HCC
screening among at-risk populations similar to our study
[14]. In fact, in our study, only provider familiarity with
HBV screening and vaccination recommendations rather
than patient related factors were significantly associated
with higher rates of HBV screening. Thus, provider-
targeted interventions should address ways to enhance their
knowledge of current recommendations.
We have identified some deficit in knowledge with
respect to HBV screening modalities utilized among pro-
viders. The combination of HBsAg and Anti-HBs has been
recommended for HBV screening [22]. Nearly all provid-
ers in our study correctly included HBsAg, a test that
detects active disease, as an HBV screening test, but 48%
did not test for anti-HBs, which is necessary to assess
eligibility for vaccination. This may reflect the lack of
knowledge about the need for vaccination in this high-
risk population. Moreover, this may lead to unnecessary
Dig Dis Sci (2011) 56:1516–1523 1521
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vaccination of those already immune, thereby driving up
costs in a resource-poor healthcare system.
The most common cause of HCC among Asian Amer-
icans is CHB, and strategies for primary and secondary
HCC prevention are critical in reducing cancer disparity in
this group. In this study, we investigated provider knowl-
edge of HCC and attitudes towards HCC screening. The
majority of providers who responded were well informed
about the risk of HCC among Asian Americans with CHB
and recognized that primary prevention with HBV treat-
ment can decrease the incidence of HCC [22–24]. Sec-
ondary prevention with HCC surveillance is recommended
by national organizations. However, improvement in rates
of HCC surveillance performed by this group of safety net
healthcare providers is required in order to adhere to these
recommendations.
There are limitations to the available data on survival
benefit of HCC screening. Nevertheless, one randomized
controlled trial and other prospective observational studies
have shown that HCC screening may result in reduced
mortality, specifically when curative therapy is available
[11, 25, 26]. Similar to other survey studies, nearly all of the
providers in this study agreed that cancer surveillance should
be performed when there is strong evidence that mortality is
reduced [14] and that they had recommended HCC surveil-
lance to their patients. However, about 30% of providers
were either unsure or did not believe that HCC screening in
CHB patients improved survival and a third were unfamiliar
with the AASLD guidelines endorsing surveillance.
In this study, predictors of adherence to the AASLD
guidelines using ultrasound every 6–12 months for HCC
surveillance in at-risk populations were assessed [12]. The
most common screening modality, utilized by about two-
thirds of the respondents, was a combination of ultrasound
and AFP at the frequency of 6–12 months. However, pro-
viders also used liver enzymes and HBV viral load, as well
as radiologic modalities other than ultrasound that are not
recommended as HCC screening tests. Factors associated
with performing the recommended screening test in mul-
tivariable analysis included having a high proportion of
at-risk Asian Americans in practice and greater provider
knowledge of HBV-associated HCC. In a national survey
of 459 primary providers and specialists identified through
the American Medical Association Masterfile, Nguyen
et al. [14] showed that the physicians who had a higher
knowledge of HBV management were more likely to
screen for HCC and that the concern for malpractice risk
and the use of HCC screening as a quality measure
increased the odds of screening. In another survey of 217
family physicians, HCC screening in CHB patients was
related to years in practice, female physicians, and group
practice [27]. In contrast, we did not find an independent
association between HCC surveillance and physician
characteristics or the overall provider attitude score, which
included risk of malpractice and quality indicators.
The main limitation of this study is self-reported prac-
tice patterns, whereas the main strength is the high
response rate. However, in general self-report tends to
overestimate screening rates [28] and thus this limitation is
unlikely to threaten our finding of suboptimal reported
rates of screening for HBV and HCC by the study popu-
lation. Generalizations to other practice settings is also
limited, since surveyed practices had a high proportion of
Asians, which may result in a heightened awareness of
CHB and HCC disease that can underestimate the defi-
ciencies in provider knowledge and rates of HBV and HCC
screening in other practice settings with lower at-risk
patient populations. Nevertheless, our findings uncovered
suboptimal HBV screening and vaccination rates even
among providers with high exposure to at-risk populations.
As several factors including patient adherence likely play a
role in rates of HBV screening, vaccination, and HCC
surveillance, review of patient health records are required
to confirm results obtained from provider reports.
In summary, our findings suggest that HBV screening
and vaccination of eligible patients and education about the
recommended tests for HBV screening and HCC surveil-
lance are potential areas requiring improvement among
providers. However, safety net providers are knowledge-
able about cancer disparity among Asian Americans and
are motivated to perform HCC surveillance even in the
presence of limited resources. Our research supports the
findings of the recent Institute of Medicine Report on
Hepatitis and Liver Cancer [17] that ongoing education of
patients and providers as well as investment in infrastruc-
ture to improve access to and quality of HBV care are key
intervention strategies to reduce the HBV disease burden
and the related cancer disparity among Asian Americans.
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